Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H1 2018

  • ID: 4479892
  • Report
  • 48 pages
  • Global Markets Direct
1 of 5
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H1 2018

Summary:

According to the recently published report 'Cholesteryl Ester Transfer Protein - Pipeline Review, H1 2018'; Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes.

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Cholesteryl ester transfer protein (CETP), also called plasma lipid transfer protein is a plasma protein that promotes the transfer of cholesteryl esters from anti-atherogenic HDLs to proatherogenic apolipoprotein B (apoB)-containing lipoproteins, including VLDLs, VLDL remnants, IDLs, and LDLs. A deficiency of CETP is associated with increased HDL levels and decreased LDL levels, a profile that is typically anti-atherogenic.

The report 'Cholesteryl Ester Transfer Protein - Pipeline Review, H1 2018' outlays comprehensive information on the Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 1 and 1 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Cardiovascular and Metabolic Disorders which include indications Dyslipidemia, Acute Coronary Syndrome, Atherosclerosis, Cardiovascular Disease, Coronary Disease and Hyperlipidemia.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)
  • The report reviews Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5
Introduction

Report Coverage

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Overview

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Companies Involved in Therapeutics Development

Chong Kun Dang Pharmaceutical Corp

Kowa Co Ltd

Pfizer Inc

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Drug Profiles

CKD-508 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CKD-519 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dalcetrapib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HL-16 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

K-312 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-04445597 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CETP for Dyslipidemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Dormant Products

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Discontinued Products

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Product Development Milestones

Featured News & Press Releases

Aug 28, 2017: DalCor Achieves 50 percent Enrollment Milestone for Phase 3 Cardiovascular Trial

Mar 07, 2017: DalCor's Phase 3 Cardiovascular Trial, dal-GenE, Exceeds Targeted Enrollment Schedule

Nov 10, 2016: DalCor Announces Data to be Presented at the American Heart Association Scientific Sessions 2016 in New Orleans

Aug 23, 2016: DalCor Announces Opening of International Trial Sites for Its Dal-GenE Phase 3 Cardiovascular Outcomes Trial

Jul 18, 2016: DalCor Dalcetrapib Demonstrates Genotype-Dependent Effects on Cholesterol Efflux and Inflammation in Data Published by The Montreal Heart Institute in Circulation: Cardiovascular Genetics

Apr 26, 2016: DalCor Randomizes First Patient in the DalGenE Phase 3 Cardiovascular Outcomes Trial

Jun 08, 2015: DalCor Pharma licenses a late-stage investigational cardiovascular drug following major scientific discovery

Jan 12, 2015: A World First - Discovery of a personalized therapy for cardiovascular disease

Nov 05, 2012: Roche's Dalcetrapib Increases HDL Levels But Fails To Reduce Risk Of Cardiovascular Events, Study Finds

May 07, 2012: Roche Provides Update On Phase III Study Of Dalcetrapib

Sep 13, 2011: Study Shows Efficacy Of Imaging Technology In Evaluating Heart Disease Drug Dalcetrapib

Aug 29, 2011: Roche Announces Results From Two Exploratory Phase IIb Studies Of Dalcetrapib

Apr 01, 2011: Roche Announces Dalcetrapib Phase II Studies dal-VESSEL And dal-PLAQUE Show Encouraging Results

Nov 18, 2009: Roche Announces Start Of New Atherosclerosis Study (dal-PLAQUE 2) For Dalcetrapib

Oct 20, 2004: JT And Roche Conclude Licensing Agreement On JT's Dyslipidemia Compound

Appendix

Methodology

Coverage

Secondary Research

Secondary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2018

Pipeline by Kowa Co Ltd, H1 2018

Pipeline by Pfizer Inc, H1 2018

Dormant Projects, H1 2018

Discontinued Products, H1 2018

Discontinued Products, H1 2018 (Contd..1), H1 2018

Discontinued Products, H1 2018 (Contd..2), H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Chong Kun Dang Pharmaceutical Corp
  • Kowa Co Ltd
  • Pfizer Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll